Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John F O'Toole

Showing results (1-10 of 61) with videos related to

Pageof 7
Sort By:
International Journal of Nephrology and Renovascular Disease|February 12, 2014
Renal manifestations of genetic mitochondrial diseaseJohn F O'Toole
Nephron. Physiology|November 13, 2010
Disorders of calcium metabolismJohn F O'Toole
The Journal of Clinical Investigation|June 4, 2014
Kidney disease: new technologies translate mechanisms to cureJohn F O'Toole, John R Sedor
Plos One|October 12, 2013
Mitochondrial aminopeptidase deletion increases chronological lifespan and oxidative stress resistance while decreasing respiratory metabolism in S. cerevisiaeErine M Stames, John F O'Toole
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|May 6, 2018
CKD, Genetic Variation, and the Epigenome: Decrypting the CodeJohn F O'Toole, John R Sedor
Journal of the American Society of Nephrology : JASN|March 5, 2011
Are cubilin (CUBN) variants at the heart of urinary albumin excretion?John F O'Toole, John R Sedor
Clinical and Experimental Nephrology|November 16, 2013
The biology of APOL1 with insights into the association between APOL1 variants and chronic kidney diseaseSethu M Madhavan, John F O'Toole
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 3, 2022
Moving Toward a Common Pathogenic Mechanism and Therapeutic Targets for APOL1 NephropathiesLeslie A Bruggeman, Timur Azhibekov, John F O'Toole
Clinical Journal of the American Society of Nephrology : CJASN|October 21, 2017
APOL1 and Proteinuria in the AASK: Unraveling the Pathobiology of APOL1John F O'Toole, Leslie A Bruggeman, John R Sedor
Current Opinion in Nephrology and Hypertension|March 26, 2021
Apolipoprotein L1 and mechanisms of kidney disease susceptibilityLeslie A Bruggeman, John R Sedor, John F O'Toole
Pageof 7

Showing results (1-10 of 61) with videos related to

Sort By:
Pageof 7
International Journal of Nephrology and Renovascular Disease|February 12, 2014
Renal manifestations of genetic mitochondrial diseaseJohn F O'Toole
Nephron. Physiology|November 13, 2010
Disorders of calcium metabolismJohn F O'Toole
The Journal of Clinical Investigation|June 4, 2014
Kidney disease: new technologies translate mechanisms to cureJohn F O'Toole, John R Sedor
Plos One|October 12, 2013
Mitochondrial aminopeptidase deletion increases chronological lifespan and oxidative stress resistance while decreasing respiratory metabolism in S. cerevisiaeErine M Stames, John F O'Toole
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|May 6, 2018
CKD, Genetic Variation, and the Epigenome: Decrypting the CodeJohn F O'Toole, John R Sedor
Journal of the American Society of Nephrology : JASN|March 5, 2011
Are cubilin (CUBN) variants at the heart of urinary albumin excretion?John F O'Toole, John R Sedor
Clinical and Experimental Nephrology|November 16, 2013
The biology of APOL1 with insights into the association between APOL1 variants and chronic kidney diseaseSethu M Madhavan, John F O'Toole
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 3, 2022
Moving Toward a Common Pathogenic Mechanism and Therapeutic Targets for APOL1 NephropathiesLeslie A Bruggeman, Timur Azhibekov, John F O'Toole
Clinical Journal of the American Society of Nephrology : CJASN|October 21, 2017
APOL1 and Proteinuria in the AASK: Unraveling the Pathobiology of APOL1John F O'Toole, Leslie A Bruggeman, John R Sedor
Current Opinion in Nephrology and Hypertension|March 26, 2021
Apolipoprotein L1 and mechanisms of kidney disease susceptibilityLeslie A Bruggeman, John R Sedor, John F O'Toole
Pageof 7